Key Stats for UnitedHealth Stock
- Current Price: $277.26
- Target Price (Mid): $578.69
- Street Target: $357.81
- Potential Total Return: +108.7%
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
UnitedHealth Group (UNH) stock has fallen 54% from its 52-week high of $606.36 to $277.26, stripping the company of its blue-chip status and forcing a debate that has no clean answer.
Bulls say the selloff is cyclical and the stock trades at a decade-low valuation. Bears say a DOJ criminal investigation, contracting membership, and a broken Medicare reimbursement model make the recovery narrative harder to trust than management’s tone implies. Q1 2026 earnings arrive on April 21, and investors want to know whether the worst is priced in or whether this stock has further to fall.
The sharpest moment of the collapse came on January 27, 2026.
UNH reported Q4 2025 revenue of $113.2 billion, missing the $113.7 billion consensus. On the same morning, the Centers for Medicare and Medicaid Services (CMS) proposed a 0.09% rate increase for Medicare Advantage (privately run Medicare plans) in 2027, far below the 6% analysts had expected.
The stock fell nearly 20% in a single session, reaching a max drawdown of 60.34% from its all-time high.
On the Q4 call, Chairman and CEO Stephen Hemsley told investors: “We confronted challenges directly and finished 2025 as a much stronger company, giving us the momentum to better serve those who count on us and continue to improve our core performance.”
His team guided 2026 adjusted EPS above $17.75, at least 8.6% growth from 2025’s $16.35 adjusted EPS, while projecting a total membership decline of more than 3 million as the company exits underpriced Medicare Advantage and Medicaid markets.
That exit was deliberate.
Tim Noel, CEO of UnitedHealthcare, said on the same call: “Our 2026 approach favored margin recovery over any specific membership targets.”
See historical and forward estimates for UnitedHealth stock (It’s free!) >>>
Is UnitedHealth Undervalued Today?
At 15.53x NTM P/E and 11.42x NTM EV/EBITDA, UNH trades at some of its lowest forward multiples in years, against a 10-year revenue CAGR of 11.0%. The stock yields 3.2% on the dividend alone.
The bear case is not easily dismissed. The DOJ’s criminal and civil investigations into UNH’s Medicare Advantage billing practices remain open with no resolution timeline.
The probe centers on whether UNH inflated patient diagnoses to trigger higher government reimbursements.
Outcomes range from a manageable settlement to, in a worst-case scenario, forced restructuring of Optum’s physician business, which sits at the core of UNH’s integrated care model.
The margin damage is real.
Adjusted EPS collapsed 40.9% year over year in 2025, and EBITDA fell 35.9% to $23.325 billion from $36.33 billion in 2023.
Optum Health swung from $7.77 billion in operating income in 2024 to a $278 million operating loss in 2025, and is now under restructuring.
UNH’s medical care ratio (MCR, the share of premium revenue paid out as claims) came in at 89.1% for full-year 2025, reflecting Medicare Advantage cost trends approaching 10% while reimbursements lagged. Management guided the 2026 MCR to 88.8% on the Q4 2025 earnings call.
The recovery case, if it holds, is compelling.
TIKR consensus projects EBITDA recovering to $27.827 billion in 2026 and $29.69 billion in 2027.
UnitedHealthcare’s repricing was approximately 90% complete heading into 2026, per Q4 management commentary, targeting double-digit operating earnings growth in that segment this year.
See how UnitedHealth performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $277.26
- Target Price (Mid): $578.69
- Potential Total Return: +108.7%
- Annualized IRR: 16.8% / year
See analysts’ growth forecasts and price targets for UnitedHealth stock (It’s free!) >>>
The mid-case model uses a 5.0% revenue CAGR and 5.0% net income margin, both below UNH’s 10-year historical revenue CAGR of 11.0% and its pre-2025 net income margin of 6.3%–6.4%.
Two revenue drivers support the case. First, UnitedHealthcare’s repricing across commercial and Medicare segments, which management said was approximately 90% complete for 2026 on the Q4 2025 earnings call, is the primary mechanism for targeted double-digit operating earnings growth in that segment. Second, Optum Rx signed over 800 new customer relationships in its 2025 selling season, a pipeline management said will scale through 2026 and 2027.
The margin driver is AI-enabled cost reduction. UNH is targeting nearly $1 billion in operating cost reductions in 2026, with approximately $1.5 billion in planned AI investment and over 80% of member calls already leveraging AI tools, per Q4 2025 management guidance.
The primary risk is the DOJ investigation. Forced restructuring of Optum’s physician assets would undermine the integrated model that the 5.0% margin assumption depends on. Even TIKR’s low scenario projects a $664.15 stock price (139.5% total return, 10.5% IRR) by 12/31/30, while the high scenario reaches $999.87 (260.6% total return, 15.8% IRR). The mid-case sits between those and requires neither full margin recovery to historical levels nor a clean legal resolution.
As Hemsley closed the Q4 call, “The momentum inside this organization is palpable. We still have work to do to continue to successfully build and progress over the next several months.”
Conclusion: Watch the medical care ratio at Q1 2026 earnings on April 21. Management guided 88.8% for the full year. A Q1 print meaningfully above that range signals the repricing isn’t holding and would reset the recovery thesis. A print in line or better validates the margin trajectory and the path toward the TIKR mid-case target.
UNH at $277.26 is not a simple buy. It is a bet that a $447.6 billion revenue company can execute a margin recovery while navigating two federal investigations, a 3-million-member contraction, and the final year of a $6 billion Medicare coding headwind. The TIKR model says the market is dramatically underpricing what comes next if execution holds. The DOJ investigation says the market may be right to wait.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in UnitedHealth?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up UnitedHealth, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track UnitedHealth alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze UnitedHealth on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
